NYSE:GLP

Global Partners Lp Stock News

Energy > Oil & Gas Midstream

Buy GLP

*Your capital is at risk

$48.45

-0.81 (-1.64%)

At Close: Jun 03, 2026

Jefferies trims Novo Nordisk target as GLP-1 pricing erosion and oral Wegovy launch uncertainty cloud first quarter

12:17pm, Tuesday, 24'th Mar 2026

The broker retains its hold rating, warning that overall portfolio growth may stall even as the oral weight-loss pill gains traction Jefferies has trimmed its price target on Novo Nordisk (NYSE:NVO),

Lexaria's Oral GLP-1 Drug Strategy Validated by Industry

09:15am, Tuesday, 24'th Mar 2026

"The window to shape the oral GLP-1 market is open now

GLP-1 And Private Labels Are A Genuine Threat To General Mills But I May Buy This Dip

08:42am, Tuesday, 24'th Mar 2026

General Mills (GIS) is rated a soft buy as its valuation appears attractive after a prolonged decline, despite recent underperformance. GLP-1 appetite-suppressing drugs and rising private label popula

Are GLP-1 Drugs Becoming a Meaningful Revenue Driver for CAH Stock?

12:30pm, Monday, 23'rd Mar 2026

CAH sees GLP-1 drugs boost revenue growth, but margins lag as strong demand lifts volumes without significantly improving profitability.

Global Partners LP COO Sells Nearly $740000 Worth of Units

11:38pm, Saturday, 21'st Mar 2026

This gasoline distributor's stock has increased so far in 2026. But how will the current geopolitical tensions threatening oil supply affect its performance?

GLP-1 drugs are changing how Americans eat. Food companies are racing to catch up

08:00am, Saturday, 21'st Mar 2026

For restaurants and food companies, the increasing adoption of GLP-1 drugs present both an opportunity and a threat to their businesses. About one in every eight U.S. adults is currently taking a GLP-

Lilly GLP-1 drug rivals Novo's pipeline treatment on gut side effects but throws up skin concern

07:15am, Friday, 20'th Mar 2026

New trial data complicates the competitive picture in the fast-growing obesity drug market Eli Lilly and Co's (NYSE:LLY) experimental weight-loss and diabetes drug retatrutide has shown a side-effect

India's weight-loss drug boom: Novo Nordisk talks about GLP-1 generics after patent expiry

03:23am, Friday, 20'th Mar 2026

The patent on semaglutide, found in Novo Nordisk's Ozempic and Wegovy weight-loss drugs, expired in India on March 20. Vikrant Shrotriya, managing director at Novo Nordisk India, talks about how gener

Is It Too Late to Buy Eli Lilly?

11:15am, Thursday, 19'th Mar 2026

Eli Lilly's Mounjaro and Zepbound are the leading drugs in the GLP-1 space. The company's GLP-1 success has resulted in a lofty valuation for the stock.

Healthy Returns: Stopping GLP-1s raises risk of heart attack, stroke and death, study says

02:06pm, Wednesday, 18'th Mar 2026

Research finds that even short gaps in treatment with a GLP-1 can drive up risks of heart attack, stroke and death in patients with Type 2 diabetes.

Why Did Eli Lilly Stock Slide 6% Despite Strong GLP-1 Momentum?

12:06pm, Wednesday, 18'th Mar 2026

LLY stock falls 6% after an HSBC downgrade flagged persisting U.S. pricing pressure, rising market competition and compounded tirzepatide risks, despite strong GLP-1 demand.

MetaVia Advances GLP-1-Based Obesity Program with IRB Approval for Higher-Dose Phase 1 Studies of DA-1726, a GLP-1 and Glucagon Dual Agonist Demonstrating Best-in-Class Potential for Weight Loss and Glucose Control

08:00am, Wednesday, 18'th Mar 2026

16-Week Study to Evaluate One-Step Dose Titration to 48 mg and Two-Step Dose Titration to 64 mg in Obese Otherwise Healthy Adults CAMBRIDGE, Mass., March 18, 2026 /PRNewswire/ -- MetaVia Inc. (Nasdaq:

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by